• 
  Thomas Lambin, Aurelien Amiot, Carmen Stefanescu, Jean-Marc M Gornet, Philippe Seksik, et al.. Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. Digestive and Liver Disease, 2020, 52 (11), pp.1323-1330. ⟨10.1016/j.dld.2020.08.034⟩. ⟨hal-03228850⟩
• 
  Julien Tap, Aurélien Amiot, Véronique Jarrousse, Sandra Guilmeau, Jeanne Tran Vannhieu, et al.. Early Phenotypical Changes Induced By Transfer Of Human Fecal Microbiota from Colorectal Cancer Patients To Germ-Free Mice. International Journal of Cancer and Oncology, 2017, 4 (1), pp. 1-11. ⟨10.15436/2377-0902.16.1128⟩. ⟨hal-03825702⟩
• 
  Nicolas Petitdidier, Laurent Beaugerie, Franck Carbonnel, Anne Bourrier, Xavier Treton, et al.. Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, pp.609 - 618. ⟨10.1016/j.clinre.2019.11.008⟩. ⟨hal-03492351⟩
• 
  J.-C. Delchier, S. Bastuji-Garin, J. Raymond, F. Megraud, A. Amiot, et al.. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection. Médecine et Maladies Infectieuses, 2020, 50, pp.492 - 499. ⟨10.1016/j.medmal.2019.06.001⟩. ⟨hal-03477218⟩
• 
  Nicolas Petitdidier, Jenny Tannoury, Nicola De’angelis, Charlotte Gagniere, Anne Hulin, et al.. Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. Digestive and Liver Disease, 2019, 51, pp.1652 - 1660. ⟨10.1016/j.dld.2019.08.020⟩. ⟨hal-03489097⟩
• 
  Aurelien Amiot, Philippe Seksik, Jean-Marie Reimund, Maria Nachury, Romain Altwegg, et al.. Prevalence of anti-TNF contraindications in Crohn’s disease: A cross-sectional survey from the GETAID. Digestive and Liver Disease, 2022, 54 (10), pp.1350-1357. ⟨10.1016/j.dld.2022.04.011⟩. ⟨hal-03690498⟩
• 
  Emma Bergsten, Denis Mestivier, Francoise Donnadieu, Thierry Pedron, Landry Tsoumtsa, et al.. Parvimonas micra , an oral pathobiont associated with colorectal cancer, epigenetically reprograms human primary intestinal epithelial cells. 2022. ⟨pasteur-03689065⟩
• 
  Massa Saab. Etude de microbiote biliaire associé aux cholangiocarcinomes (CCA) et caractérisation des mécanismes impliqués. Médecine humaine et pathologie. Université Paris-Est, 2021. Français. ⟨NNT : 2021PESC0053⟩. ⟨tel-03667959⟩
• 
  Tullia de Risi-Pugliese, Philippe Seksik, Jean-David Bouaziz, François Chasset, Philippe Moguelet, et al.. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study. Journal of The American Academy of Dermatology, 2019, 80, pp.781 - 784. ⟨10.1016/j.jaad.2018.06.065⟩. ⟨hal-03484654⟩
• 
  Sara Tadbiri, Maria Nachury, Yoram Bouhnik, Mélanie Serrero, Xavier Hebuterne, et al.. The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2021, 15 (5), pp.766-773. ⟨10.1093/ecco-jcc/jjaa244⟩. ⟨hal-03038348⟩

15

30